Phanes Therapeutics names new VP of Business Development
12 January 2022 -

Phanes Therapeutics Inc, a US-based company that deals with innovative discovery research in immuno-oncology, announced on Tuesday that it has named Paul Chu, MBA, as its vice president of Business Development.

Chu has held senior leadership roles in both small biotech companies and large multi-national corporations. He has served as vice president of Business Development at HUYABIO International. He has held similar roles at AiViva BioPharma and UroGen Pharma and earlier in his career was director of Business Development at Allergan, Inc. where he spearheaded multiple M&A transactions.

Dr Ming Wang, founder and CEO, said, 'We welcome Paul to the Phanes family and are delighted to appoint a professional of his calibre as vice president of Business Development. We have built a strong pipeline in immuno-oncology by leveraging our proprietary technology platforms and expect to file 3 INDs in 2022, including one best-in-class monoclonal antibody (mAb) program and two first-in-class bispecific antibody programs. We look forward to benefitting from Paul's extensive experience and network in Oncology as we enter 2022, which we expect to be a transformational year for Phanes.'